Skip to main content
. 2026 Jan 1;16(6):2952–2983. doi: 10.7150/thno.124189

Figure 4.

Figure 4

In vitro antitumor and antimetastatic activities of MCT-NEs. (A) Schematic illustration of the cytotoxicity assessment of ATV and/or DTX in 4T1 cells under MTD or MCT regimens. (B) Combined effects of ATV/DTX delivered in 0.5% DMSO or MCT-NE#9 on 4T1 cells at different ATV-to-DTX weight ratios (mean ± SD, n = 4). (C) Cytotoxic responses of ATV/DTX in 0.5% DMSO or MCT-NE#9 following MTD or MCT schedules (mean ± SD, n = 4). (D, E) Quantification and representative images of 4T1 cell adhesion to ECM proteins (fibronectin, collagen I, collagen IV, laminin I, fibrinogen, and BSA) in 48-well plates (mean ± SD, n = 4). (F) Inhibitory effects of ATV/DTX in 0.5% DMSO or MCT-NE#9 on 4T1 cell migration and invasion under MTD or MCT treatment conditions (mean ± SD, n = 3). * p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001.